The global crisis caused by the coronavirus disease 2019 (COVID-19) led to the most significant economic loss and human deaths after World War II The pathogen causing this disease is a novel virus called the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) As of December 2020, there have been 80 2 million confirmed patients, and the mortality rate is known as 2 16% globally A strategy to protect a host from SARS-CoV-2 is by suppressing intracellular viral replication or preventing viral entry We focused on the spike glycoprotein that is responsible for the entry of SARS-CoV-2 into the host cell Recently, the US Food and Drug Administration/EU Medicines Agency authorized a vaccine and antibody to treat COVID-19 patients by emergency use approval in the absence of long-term clinical trials Both commercial and academic efforts to develop preventive and therapeutic agents continue all over the world In this review, we present a perspective on current reports about the spike glycoprotein of SARS-CoV-2 as a therapeutic target
Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target